Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Public ClinicalTrials.gov record NCT06333951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.
Study identification
- NCT ID
- NCT06333951
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Interventions
- Anvumetostat Drug
- Carboplatin Drug
- Paclitaxel Drug
- Pembrolizumab Drug
- Pemetrexed Drug
- Sotorasib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2024 (Actual)
- Primary completion
- Oct 31, 2026 (Estimated)
- Completion
- Nov 30, 2026 (Estimated)
- Last update posted
- May 28, 2026
2024 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Duarte | California | 91010 | — |
| Translational Research in Oncology US Inc, Trio Central Pharmacy | Los Angeles | California | 90095 | — |
| University of California Irvine | Orange | California | 92868-3217 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| HealthPartners Institute | Saint Paul | Minnesota | 55102 | — |
| Saint Lukes Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 32224 | — |
| New York University Grossman School of Medicine | New York | New York | 10016 | — |
| Perlmutter Cancer Center at New York University Langone Hospital----Long Island | New York | New York | 10016 | — |
| Upstate University Hospital | Syracuse | New York | 13210 | — |
| Hightower Clinical | Oklahoma City | Oklahoma | 73102 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| University of Tennessee Medical Center Knoxville | Knoxville | Tennessee | 37920 | — |
| United States Oncology Regulatory Affairs Corporate Office | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Dallas Fort Worth | Dallas | Texas | 75246 | — |
| US Oncology Research Investigational Products Center | Dallas | Texas | 75246 | — |
| Oncology Consultants Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology Northeast Texas | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists PC | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06333951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06333951 live on ClinicalTrials.gov.